Muscle optimization device and method

22 Pages·2015·2.37 MB·English

US 20140288471A1
(19) United States
(12) Patent Application Publication (10) Pub. No.: US 2014/0288471 A1
Gangwish et al. (43) Pub. Date: Sep. 25, 2014
(54) MUSCLE OPTIMIZATION DEVICE AND (52) U.S.Cl.
METHOD
CPC .............. .. A61H23/00(2013.01);A61H1/008
(2013.01)
(71) ApplicantszKimberly S. GangWish, Louisville, CO
USPC .......................................................... .. 601/46
(US); Charles T. Krebs, Belmont, MA
(Us)
(57) ABSTRACT
(72) Inventors: Kimberly S. GangWish, Louisville, CO
(US); Charles T. Krebs, Belmont, MA
(Us) A device and method are provided for therapy and treatment
of biological tissue such as muscle, tendon, and ligament
(73) Assignee: GENOVUS BIOTECHNOLOGIES tissue, by use of a device and method in Which therapeutic
INC., Louisville, CO (US) vibrational frequency resonance patterns are transmitted to
tissues of a patient. The resonance frequencies originate from
(21) Appl. No.: 14/219,623 many resonance domains, including vitamins, minerals,
herbs, amino acids, and fatty acids. Each domain includes
(22) Filed: Mar. 19, 2014 therapeutic frequency resonance patterns. These resonance
patterns are identi?ed, captured, and ultimately delivered to a
Related US. Application Data mineral matrix component of the device. The combined reso
(60) Provisional application No. 61/803,395, ?led on Mar. nance patterns are embedded in a mineral matrix that includes
selected minerals and elements and is capable of retaining the
1 9, 2013.
combined or master frequency resonance patterns for a period
Publication Classi?cation of time. Resonance frequencies retained by the mineral
matrix are transmitted to a patient to enhance tissue function,
(51) Int. Cl. to decrease the normal rehabilitation time of a damaged tis
A 61H 23/00 (2006.01) sue, and provide therapeutic bene?ts for muscle tissue dys
A 61H 1/00 (2006.01 ) function.
20
*1 LOCATE MUSCLE IMBALANCE
22
POSITION MUSCLE IN FURTHEST
STATE OF CONTRACTION (26
I C O I CONTINUE To ‘
.v ‘ EVALUATE PATIENT ;
~ ’ TO FIND
CHANGE /./ ’ |MBALENCE(S)
1 CHANGE ‘1
28 I OBSERVED 1
V
\__i PLACE DEVICE ON PATIENT
30
POSITION MUSCLE IN FURTHEST
STATE OF c ONTRACTION
32 APPLY INCREASING PRESSURE TO
MUSCLE
3”)
REPEAT APPLICATION OF PRESSURE TO
OBSERVE IMPROVEMENT
36 V
REMOVE DEV CE AND REST
MUSCLE
38 ‘
>\‘ RETEST MUSCLE
Patent Application Publication Sep. 25, 2014 Sheet 1 of 11 US 2014/0288471 A1
To Trapezius
for fixation
g Sensory Neuron
\ (facilitated) / from Spindle Cell
A I
Alpha Motor Neuron
/ to Prime Mover
/Alplia Motor Neuron
to Antagonist(s)
(—~\
Alpha Motor Neuron
to Synergist(s)
Alpha Motor Neuron
from Spinal Segment
Alpha Motor Neuron
to Antagonist Sensory Neuron
from Spindle Cell to \
Spinal Segment I
Alpha Motor Neuron
to Synergist Prime Mover
(facilitated)
Antagonist(s)
(inhibited)
Synergist(s)
(facilitated)
Fig. 1
Prior Art
Patent Application Publication Sep. 25, 2014 Sheet 2 0f 11 US 2014/0288471 A1
Patent Application Publication Sep. 25, 2014 Sheet 3 0f 11 US 2014/0288471 A1
20'7L\\\
LOCATE MUSCLE IMBALANCE
22 I,
K POSITION MUSCLE IN FURTHEST
STATE OF CONTRACTION
/
24 / /M/U STCELSET F OR‘ CHXSGE EVACLOUNATTIEN UPEA TTIOE NT I
INDICATOR To FIND I
\ CHANGE IMBALENCE(S)
\\ ,f"
IOBSERVEDI
28 1
PLACE DEVICE ON PATIENT
7
POSITION MUSCLE IN FURTHEST
STATE OF CONTRACTION
V
32 L APPLY INCREASI \IG PRESSURE TO
MUSCLE
34 V
1 REPEAT APPLICATION OF PRESSURE TO
OBSERVE IMPROVEMENT
V
36 k REMOVE DEVICE AND REST
MUSCLE
38 V
k RE~TEST MUSCLE
FIG. 3
Patent Application Publication Sep. 25, 2014 Sheet 4 0f 11 US 2014/0288471 A1
40 \
PREPARE MUSCLE FORMULA
i 42
v
DISSOLVE MUSCLE FORMULA IN
SOLUTION
44 V
K PROVIDE FIRST CHAMBER WITH SOLUTION
THEREIN
LOCATE LAZER ADJACENT FIRST
CHAMBER
48
v
K PROVIDE SECOND CHAMBER WITH MASTER
CRYSTAL THEREIN
\
50 Q ACTIVATE LASER TO PASS
THROUGH CHAMBERS
V
MASTER CRYSTAL CREATED
2
5 L- WITH MF FREQUENCY
RESONANCE MATRIX
54 r
K TRANSMIT MF FREQUENCY MATRIX TO CHIP BY
LASER THROUGH MASTER CRYSTAL
56 K ‘
ADD PROTECTIVE LAYER TO CHIP
FIG. 4
Patent Application Publication Sep. 25, 2014 Sheet 5 0f 11 US 2014/0288471 A1
PSU[E‘tLiTE
9
'03
CD
(D
1393 L0
320 In.
2% .
IE U)
v- ”—-'" I—
4-;
(D
ww-mmwmm
1"?" IIIlIIC-J

Patent Application Publication Sep. 25, 2014 Sheet 7 0f 11 US 2014/0288471 A1
F7ig.
a; m a I: 2 a?
Patent Application Publication Sep. 25, 2014 Sheet 8 of 11 US 2014/0288471 A1
45
35
cipfPeohreracnecannegtk e
N O
10 ~
Chip Applied Post "Treatment"
Condition
W Control Subjects — Experimental Subjects Threshold
Fig. 8
Patent Application Publication Sep. 25, 2014 Sheet 9 of 11 US 2014/0288471 A1
012
0.1
0.08
(MRemMavSn)
0.04
0.02
Baseline Chip Applied Post "Treatment"
Condition
15% Control Subjects I Experimental Subjects
Fig. 9